sur Alamar Biosciences, Inc.
Alamar Biosciences Secures $50 Million Through Oversubscribed Financing and Expands Leadership
Alamar Biosciences, a leader in precision proteomics, announced the successful close of an oversubscribed convertible notes financing, raising over $50 million. New participants in this financing round include T. Rowe Price Investment Management and Braidwell LP. Existing investors such as Illumina Ventures and Sands Capital also contributed. This capital influx aims to enhance Alamar's precision proteomics platform, designed for early disease detection.
The company is reinforcing its leadership team with key appointments. Dr. Stephen Williams has joined as Chief Scientific Officer, bringing over 30 years of experience from roles at Standard BioTools, SomaLogic, and Pfizer. Additionally, Rebecca Chambers and Dr. Frank Witney have been appointed to the Board of Directors, offering substantial expertise in healthcare and life sciences.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Alamar Biosciences, Inc.